Rainier Acquisition Corporation Announces Full Exercise of Over-Allotment Option, Bringing Total IPO Gross Proceeds to $86,250,000

Rainier Acquisition Corporation (RNAQ) reported that the underwriter of its initial public offering fully exercised its over-allotment option on September 2, 2026, purchasing an additional 1,125,000 units at $10.00 per unit.

Rhea-AI Summary

Rainier Acquisition Corporation (RNAQ) reported that the underwriter of its initial public offering fully exercised its over-allotment option on September 2, 2026, purchasing an additional 1,125,000 units at $10.00 per unit.

This closing increased total units sold in the IPO to 8,625,000 and aggregate gross proceeds to $86,250,000, before underwriting discounts and offering expenses. An equal amount of $86,250,000, or $10.00 per unit, is now held in the company’s trust account. Each unit includes one Class A ordinary share and one-quarter of one redeemable warrant, with each whole warrant exercisable for one Class A ordinary share at $11.50 per share. The units began trading on the Nasdaq Capital Market on August 27, 2026 under the ticker “RNAQU,” and the Class A ordinary shares and warrants are expected to trade separately as “RNAQ” and “RNAQW,” respectively. Rainier is a special purpose acquisition company targeting business combinations in global life sciences sectors, led by CEO Gbola Amusa and CFO Guy Barudin.

Positive

• Over-allotment fully exercised for 1,125,000 units at $10.00 each
• Total IPO gross proceeds of $86,250,000 before fees and expenses
• $86,250,000 placed in trust account at $10.00 per unit
• Warrants exercisable at $11.50 per Class A share

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, NY, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rainier Acquisition Corporation (the "Company") announced today that the underwriter of its previously announced initial public offering has exercised in full its over-allotment option to purchase an additional 1,125,000 units at a price of $10.00 per unit. The closing of the over-allotment option on September 2, 2026 brought total units sold in the initial public offering to 8,625,000 units and aggregate gross proceeds to $86,250,000, before underwriting discounts and offering expenses. Following the closing of the over-allotment option, an aggregate of $86,250,000 ($10.00 per unit sold in the initial public offering) is held in the Company’s trust account.

Each unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units began trading on the Nasdaq Capital Market on August 27, 2026 under the ticker symbol “RNAQU.” Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on The Nasdaq Capital Market under the symbols "RNAQ" and "RNAQW," respectively.

The Company is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, although its efforts to identify a prospective target business will not be limited to any particular industry or geographical region. The Company's management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer.

Chardan acted as the sole book-running manager for the offering.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at: prospectus@chardan.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on August 26, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements," including with respect to the Company's search for an initial business combination. No assurance can be given that the Company will complete an initial business combination, or that the proceeds of the offering will be used as indicated.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Gbola Amusa, Chief Executive Officer
1 Pennsylvania Plaza, Suite 4800
New York, NY 10119
Tel.: (646) 465-9000
gamusa@rainier-acq.com

FAQ

What did Rainier Acquisition Corporation (RNAQ) announce about its IPO over-allotment?

Rainier Acquisition Corporation announced that its IPO underwriter fully exercised the over-allotment option to buy 1,125,000 additional units at $10.00 per unit, bringing total units sold to 8,625,000 and gross proceeds to $86,250,000 before underwriting discounts and offering expenses.

How much did Rainier Acquisition Corporation (RNAQ) raise in total IPO gross proceeds?

Rainier Acquisition Corporation raised total IPO gross proceeds of $86,250,000 from the sale of 8,625,000 units at $10.00 per unit. The company states that this entire amount, or $10.00 per unit, is held in its trust account following the over-allotment closing.

What does each Rainier Acquisition Corporation (RNAQ) IPO unit consist of?

Each Rainier Acquisition Corporation IPO unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. Every whole warrant entitles the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, according to the company.

Under which Nasdaq ticker symbols do Rainier Acquisition Corporation (RNAQ) securities trade?

Rainier Acquisition Corporation states that its units began trading on the Nasdaq Capital Market under the ticker “RNAQU” on August 27, 2026. Once separated, the Class A ordinary shares and warrants are expected to trade under the symbols “RNAQ” and “RNAQW”, respectively.

What type of company is Rainier Acquisition Corporation (RNAQ) and what sector is it targeting?

Rainier Acquisition Corporation is a special purpose acquisition company (SPAC) formed to pursue a merger or similar business combination. The company intends to focus on global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, tools, research services, and biomanufacturing.

Who leads the management team of Rainier Acquisition Corporation (RNAQ)?

Rainier Acquisition Corporation’s management team is led by Gbola Amusa, MD, CFA, as Chief Executive Officer, and Guy Barudin as Chief Financial Officer. The company describes this team as responsible for guiding its efforts to identify and complete a business combination.

When did the SEC declare effective the registration statement for Rainier Acquisition Corporation (RNAQ)?

The registration statement for Rainier Acquisition Corporation’s securities was declared effective by the SEC on August 26, 2026. The company notes that the offering was made only by means of a prospectus filed in connection with this effective registration.